Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation

NCT07752875 is registered in ClinicalTrials.gov with LG Chem as lead sponsor.

NCT NCT07752875
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07752875 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation
Lead sponsor
LG Chem
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
December 1, 2026
Completion date
April 30, 2033
Enrollment
250 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, colorectal cancer, endometrial cancer, esophageal cancer, head and neck cancer, locally advanced unresectable or metastatic solid tumor, non small cell lung cancer, ovarian cancer, pancreatic cancer, small cell lung cancer